These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34783301)

  • 1. Anthracycline-induced cardiotoxicity in women without cardiovascular diseases: molecular and genetic predictors.
    Kopeva KV; Grakova EV; Shilov SN; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
    Acta Cardiol; 2022 Nov; 77(9):805-814. PubMed ID: 34783301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Anthra-cycline-Induced Cardiotoxicity: the Role of Genetic Predictors].
    Kopeva KV; Grakova EV; Shilov SN; Popova AA; Berezikova EN; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
    Kardiologiia; 2023 May; 63(4):22-28. PubMed ID: 37165991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
    Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
    Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-Induced Cardiotoxicity: The Role of Endothelial Dysfunction.
    Grakova EV; Shilov SN; Kopeva KV; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
    Cardiology; 2021; 146(3):315-323. PubMed ID: 33596565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of Global Longitudinal Strain and NT-proBNP on Early Development of Cardiotoxicity in Breast Cancer Patients Treated with Anthracycline-Based Chemotherapy.
    Muckiene G; Vaitiekus D; Zaliaduonyte D; Zabiela V; Verseckaite-Costa R; Vaiciuliene D; Juozaityte E; Jurkevicius R
    Medicina (Kaunas); 2023 May; 59(5):. PubMed ID: 37241185
    [No Abstract]   [Full Text] [Related]  

  • 6. Assessment of anthracycline-induced cardiotoxicity with biochemical markers.
    Horacek JM; Pudil R; Jebavy L; Tichy M; Zak P; Maly J
    Exp Oncol; 2007 Dec; 29(4):309-13. PubMed ID: 18199989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevations in High-Sensitive Cardiac Troponin T and N-Terminal Prohormone Brain Natriuretic Peptide Levels in the Serum Can Predict the Development of Anthracycline-Induced Cardiomyopathy.
    Bisoc A; Ciurescu D; Rădoi M; Tântu MM; Rogozea L; Sweidan AJ; Bota DA
    Am J Ther; 2020; 27(2):e142-e150. PubMed ID: 30648987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients.
    Romano S; Fratini S; Ricevuto E; Procaccini V; Stifano G; Mancini M; Di Mauro M; Ficorella C; Penco M
    Br J Cancer; 2011 Nov; 105(11):1663-8. PubMed ID: 22068815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
    Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
    J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series.
    Cil T; Kaplan AM; Altintas A; Akin AM; Alan S; Isikdogan A
    Clin Drug Investig; 2009; 29(2):131-7. PubMed ID: 19133708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of biomarkers and echocardiography in the evaluation of cardiotoxicity risk in children treated for leukemia.
    Raluca Maniu D; Blag C; Popa G; Bota M; Vlad C; Cainap C; Balacescu O; Pop L; Cainap SS
    J BUON; 2018 Dec; 23(7):122-131. PubMed ID: 30722121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms rs4673 and rs28714259 in predicting anthracycline-mediated cardiotoxicity in patients with breast cancer.
    Gvaldin GD; Timoshkina TN; Vladimirova L; Svetitskaya SY; Vaschenko VL
    Klin Onkol; 2021; 34(6):463-466. PubMed ID: 34911332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity of anthracycline (ANT) treatment in children with malignant tumors.
    Hu H; Zhang W; Huang D; Yang Q; Li J; Gao Y
    Pediatr Hematol Oncol; 2018 Mar; 35(2):111-120. PubMed ID: 29648903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of TNF-α, Fas/Fas ligand system and NT-proBNP in the early detection of asymptomatic left ventricular dysfunction in cancer patients treated with anthracyclines.
    Kouloubinis A; Sofroniadou S; Panoulas VF; Makaritsis K; Revela I; Karavolias G; Voudris V; Adamopoulos S
    Int J Cardiol Heart Vasc; 2015 Mar; 6():85-90. PubMed ID: 28785633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.
    Demissei BG; Hubbard RA; Zhang L; Smith AM; Sheline K; McDonald C; Narayan V; Domchek SM; DeMichele A; Shah P; Clark AS; Fox K; Matro J; Bradbury AR; Knollman H; Getz KD; Armenian SH; Januzzi JL; Tang WHW; Liu P; Ky B
    J Am Heart Assoc; 2020 Jan; 9(2):e014708. PubMed ID: 31959034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis.
    Michel L; Mincu RI; Mrotzek SM; Korste S; Neudorf U; Rassaf T; Totzeck M
    ESC Heart Fail; 2020 Apr; 7(2):423-433. PubMed ID: 32069386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetranectin as a potential novel prognostic biomarker in anthracycline-related cardiac dysfunction.
    Kopeva KV; Grakova EV; Shilov SN; Berezikova EN; Bobyleva ET; Teplyakov AT
    Heart Vessels; 2023 Oct; 38(10):1256-1266. PubMed ID: 37310463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic role of p53 gene polymorphism in risk assessment of anthracycline-induced cardiotoxicity].
    Shilov SN; Teplyakov AT; Popova AA; Berezikova EN; Neupokoeva MN; Grakova EV; Valeeva AM; Tuleutaev SM
    Kardiologiia; 2019 Aug; 59(7S):15-22. PubMed ID: 31441737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracellular matrix remodeling in anthracycline-induced cardiotoxicity: What place on the pedestal?
    Grakova EV; Shilov SN; Kopeva KV; Berezikova EN; Popova AA; Neupokoeva MN; Ratushnyak ET; Teplyakov AT
    Int J Cardiol; 2022 Mar; 350():55-61. PubMed ID: 35007649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.
    de Vries Schultink AHM; Boekhout AH; Gietema JA; Burylo AM; Dorlo TPC; van Hasselt JGC; Schellens JHM; Huitema ADR
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):431-442. PubMed ID: 29429038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.